TITLE

A successful study comparing the recently developed oral transmucosal fentanyl citrate (OTFC) with immediate release opioids for cancer breakthrough pain

AUTHOR(S)
Nugent, M; Hanks, G; Bush, M
PUB. DATE
May 2000
SOURCE
Palliative Medicine;May2000, Vol. 14 Issue 3, p229
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Evaluates the use of oral transmucosal fentanyl citrate (OTFC) for cancer breakthrough pain in Great Britain. Comparison with immediate release opioids; Definition of breakthrough pain; Safety and effectiveness of OTFC.
ACCESSION #
3128691

 

Related Articles

  • Fentanyl buccal soluble film (FBSF) for breakthrough pain in patients with cancer: a randomized, double-blind, placebo-controlled study. Rauck, R.; North, J.; Gever, L. N.; Tagarro, I.; Finn, A. L. // Annals of Oncology;Jun2010, Vol. 21 Issue 6, p1308 

    Background: Fentanyl buccal soluble film (FBSF) has been developed as a treatment of breakthrough pain in opioid-tolerant patients with cancer. The objective of this study was to evaluate the efficacy of FBSF at doses of 200–1200 μg in the management of breakthrough pain in patients...

  • Sublingual fentanyl citrate for cancer-related breakthrough pain: a pilot study. Zeppetella, G. // Palliative Medicine;Jul2001, Vol. 15 Issue 4, p323 

    The effects of sublingual fentanyl citrate (SLFC) were assessed in 11 hospice inpatients with cancer-related breakthrough pain. Patients were asked to rate their pain, using a visual analogue scale, before SLFC, then after 3, 5, 10, 15, 30, 45 and 60 min. Six patients (55%) had reductions in...

  • Transdermal fentanyl for the management of cancer pain: a survey of 1005 patients. Radbruch, L.; Sabatowski, R.; Petzke, F.; Brunsch-Radbruch, A.; Grond, S.; Lehmann, K.A. // Palliative Medicine;Jul2001, Vol. 15 Issue 4, p309 

    Transdermal fentanyl was released in Germany in 1995. From October 1996 to February 1998 transdermal treatment was documented for 1005 patients (506 men and 499 women with a mean age of 60 years, range 20-92 years) with chronic pain in an open survey including 290 physicians from hospitals and...

  • Role of Opioid Analgesics in the Treatment of Chronic Non-Cancer Pain. Strumpf, M.; dertwinkel, R.; Wiebalck, A.; Bading, B.; Zenz, M. // CNS Drugs;2000, Vol. 14 Issue 2, p147 

    For more than 15 years opioids have been administered for chronic non-cancer pain. Refractory, chronic and extreme pain - even when associated with a non-cancerous disorder - should in many cases be considered ‘malignant’ on the basis of its quality and intensity. Clinical studies...

  • A survey of the use of alternative strong opioids. Lee, B; Cole, C; Gwilliam, B; Broadley, K; Hardy, J // Palliative Medicine;May2000, Vol. 14 Issue 3, p238 

    Investigates the use of alternative strong opioids for cancer pain. Reasons for changing morphine to another opioid; Outcomes in terms of resolution of the opioid-induced adverse effects; Dosage and administration routes; Common opioid changes.

  • Dose Proportionality of Fentanyl Buccal Tablet in Doses Ranging from 600 to 1300 μg in Healthy Adult Subjects: A Randomized, Open-Label, Four-Period, Crossover, Single-Centre Study. Darwish, Mona; Kirby, Mary; Robertson Jr, Philmore; Tracewell, William; Fang Xie // Clinical Drug Investigation;2010, Vol. 30 Issue 6, p365 

    Background: Fentanyl buccal tablet (FBT) is indicated for the treatment of breakthrough pain in patients who are already receiving, and who are tolerant to, opioid therapy for underlying, persistent cancer pain. Breakthrough pain may be severe or excruciating, and some patients may require high...

  • Survey on the use of buprenorphine patches in the palliative care practice. Bourne, Flora M.; Zylicz, Zbigniew // Advances in Palliative Medicine;2010, Vol. 9 Issue 2, p39 

    Transdermal buprenorphine is a new formulation of the old drug available for the treatment of cancer and non-cancer pain. The drug offers number of interesting new features and was found effective in clinical trials in cancer patients with pain. We performed a survey of the use of buprenorphine...

  • Cancer pain management.  // Cortlandt Forum;Dec2006, Vol. 19 Issue 12, p25 

    The article reports that Cephalon Inc. has developed Fentora, a buccal tablet formulation of the opioid analgesic fentanyl, which is used in the treatment of cancer pain. The drug is not recommended for use by opioid-intolerant patients and for children less than 18 years of age. The drug is...

  • Fentanyl Pectin Nasal Spray: In Breakthrough Pain in Opioid-Tolerant Adults with Cancer. Lyseng-Williamson, Katherine A. // CNS Drugs;2011, Vol. 25 Issue 6, p511 

    Fentanyl pectin nasal spray (PecFent®) uses a novel pectin-based delivery system that turns from an aqueous solution into a gel when applied to mucosal surfaces. Fentanyl is absorbed in a controlled manner from the pectin gel formed in the nasal cavity, and has a rapid onset of pain relief...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics